Evotec announces progress in neuroscience collaboration with Bristol Myers
Squibb

EQS-News: Evotec SE / Key word(s): Miscellaneous
Evotec announces progress in neuroscience collaboration with Bristol Myers
Squibb

12.06.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

__TOKEN__0__0__

     * Key scientific achievement advances the joint pipeline in the
     strategic neuroscience partnership with Bristol Myers Squibb and
     earns a payment of US$ 20 m to Evotec to progress further research

Hamburg, Germany, 12 June 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;
NASDAQ: EVO) announced today that the Company has reached important
scientific progress within its neuroscience collaboration with Bristol Myers
Squibb (NYSE:BMY) triggering a research payment of US$ 20 m to Evotec. A
target-based programme progresses into late pre-clinical development,
further contributing to the fast-growing and promising pipeline of discovery
to clinical-stage programmes in neurodegeneration that the partnership has
generated.

Evotec and Bristol Myers Squibb entered their strategic neuroscience
collaboration in December 2016 to identify disease-modifying treatments for
a broad range of neurodegenerative diseases. Currently approved drugs mainly
offer short-term management of the patients' symptoms and there is a
significant unmet medical need for therapeutic modalities that slow down or
prevent disease progression.

A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in
September 2021 as BMS-986419. Following a successful Phase I study Bristol
Myers Squibb announced that a Phase II study for BMS-986419 is scheduled to
commence in 2024. In March 2023, Bristol Myers Squibb and Evotec extended
and expanded this partnership for an additional 8 years.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, said: "We are excited
to further expand our pipeline with another high-potential programme
progressing into late pre-clinical development, demonstrating the
exceptional productivity of our neuroscience partnership with Bristol Myers
Squibb and our shared commitment to innovation and patient care. Together
with Bristol Myers Squibb we have been able to advance a growing portfolio
of programmes to critical inflection points, bringing us closer to our joint
goal of delivering new therapeutic options for patients suffering from
devastating neurological disorders."

About Evotec SE
Evotec is a life science company with a unique business model that delivers
on its mission to discover and develop highly effective therapeutics and
make them available to the patients. The Company's multimodality platform
comprises a unique combination of innovative technologies, data and science
for the discovery, development, and production of first-in-class and
best-in-class pharmaceutical products. Evotec provides high value pipeline
co-creating partnerships and solutions to all Top 20 Pharma and over 800
biotechnology companies, academic institutions, as well as other healthcare
stakeholders. Evotec has strategic activities in a broad range of currently
underserved therapeutic areas, including e.g. neurology, oncology, as well
as metabolic and infectious diseases. Within these areas of expertise,
Evotec aims to create the world-leading co-owned pipeline for innovative
therapeutics and has to-date established a portfolio of more than 200
proprietary and co-owned R&D projects from early discovery to clinical
development. Evotec operates globally with more than 5,000 highly qualified
people. The Company's sites in Europe and the USA offer highly synergistic
technologies and services and operate as complementary clusters of
excellence. For additional information please go to www.evotec.com and
follow us on X/Twitter @Evotec and LinkedIn.

Forward-looking statements
This announcement contains forward-looking statements concerning future
events, including the proposed offering and listing of Evotec's securities.
Words such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "might," "plan," "potential," "should," "target," "would"
and variations of such words and similar expressions are intended to
identify forward-looking statements. Such statements include comments
regarding Evotec's expectations for revenues, Group EBITDA and unpartnered
R&D expenses. These forward-looking statements are based on the information
available to, and the expectations and assumptions deemed reasonable by
Evotec at the time these statements were made. No assurance can be given
that such expectations will prove to have been correct. These statements
involve known and unknown risks and are based upon a number of assumptions
and estimates, which are inherently subject to significant uncertainties and
contingencies, many of which are beyond the control of Evotec. Evotec
expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to
reflect any change in Evotec's expectations with respect thereto or any
change in events, conditions or circumstances on which any statement is
based.

For further information, please contact:

Media

Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com

Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com

Investor Relations

Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com


---------------------------------------------------------------------------

12.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Evotec SE
                   Manfred Eigen Campus / Essener Bogen 7
                   22419 Hamburg
                   Germany
   Phone:          +49 (0)40 560 81-0
   Fax:            +49 (0)40 560 81-222
   E-mail:         info@evotec.com
   Internet:       www.evotec.com
   ISIN:           DE0005664809
   WKN:            566480
   Indices:        MDAX, TecDAX
   Listed:         Regulated Market in Berlin, Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Dusseldorf, Hamburg,
                   Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
   EQS News ID:    1922805

End of News EQS News Service
---------------------------------------------------------------------------

1922805 12.06.2024 CET/CEST